Relay Therapeutics, Inc. Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Relay Therapeutics, Inc. on June 27, 2022. The filing primarily discloses a Regulation FD event regarding an anticipated registrational path for the company's lead candidate, RLY-4008, and the announcement of three new programs within its breast cancer franchise.
Key Financial Metrics
The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. As a pre-revenue biotechnology company, this 8-K focuses on clinical development milestones rather than financial performance metrics.
Material Changes and Clinical Updates
- RLY-4008 Regulatory Path: Following an end-of-phase 1 meeting with the FDA, the Company plans to proceed with a single-arm trial design for FGFRi-naïve FGFR2-fusion cholangiocarcinoma (CCA) at a dose of 70 mg once daily to potentially support accelerated approval.
- Interim Clinical Data: Data as of April 19, 2022, included a safety database of 115 patients. In the 13 FGFRi-naïve FGFR2-fusion CCA patients treated with the once-daily schedule, 8 (62%) achieved confirmed partial responses. All four patients treated at the registrational dose of 70 mg QD had confirmed partial responses.
- Safety Profile: No Grade 4 or 5 adverse events were observed. Treatment-emergent adverse events were largely reversible and manageable, with notable off-target toxicities (hyperphosphatemia and diarrhea) deemed clinically insignificant.
- Portfolio Expansion: The Company announced three new breast cancer programs: a selective CDK2 inhibitor, a rationally designed ERα degrader, and RLY-5836, a selective pan-mutant PI3Kα inhibitor.
Guidance, Outlook, and Risks
Management intends to add supportive CCA cohorts to a future New Drug Application, including frontline, FGFRi-experienced, and FGFR2 mutation/amplification patients, to potentially facilitate a line and alteration-agnostic label. The filing includes standard forward-looking statements regarding the timing of clinical trials, regulatory interactions, and cash runway projections. Risks cited include the impact of the COVID-19 pandemic, macroeconomic conditions, clinical trial delays, and the uncertainty of regulatory outcomes.
Investor Verification Checklist
- Verify the specific design and enrollment criteria for the proposed single-arm registration-enabling trial for RLY-4008.
- Confirm the timeline for the initiation of the three new breast cancer programs (CDK2, ERα, and RLY-5836).
- Review the Company's most recent Form 10-Q or 10-K for current cash position and runway, as this 8-K does not contain financial data.
- Monitor future FDA communications regarding the acceptance of the proposed accelerated approval path for RLY-4008.